Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.21 USD
Change Today +0.15 / 14.15%
Volume 1.0M
SNSS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (SNSS) Snapshot

Open
$1.09
Previous Close
$1.06
Day High
$1.22
Day Low
$1.07
52 Week High
09/29/14 - $7.78
52 Week Low
07/27/15 - $0.84
Market Cap
91.3M
Average Volume 10 Days
801.5K
EPS TTM
$-0.55
Shares Outstanding
75.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUNESIS PHARMACEUTICALS INC (SNSS)

Related News

No related news articles were found.

sunesis pharmaceuticals inc (SNSS) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (SNSS) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

39 Employees
Last Reported Date: 03/12/15
Founded in 1998

sunesis pharmaceuticals inc (SNSS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $488.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $390.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $420.9K
Compensation as of Fiscal Year 2014.

sunesis pharmaceuticals inc (SNSS) Key Developments

Sunesis Pharmaceuticals, Inc. Announces Publication of Vosaroxin Phase 3 VALOR Trial Results in The Lancet Oncology

Sunesis Pharmaceuticals, Inc. announced that results from the company's Phase 3 VALOR trial of vosaroxin and cytarabine in 711 patients with relapsed or refractory acute myeloid leukemia (AML) were published in Lancet Oncology. The VALOR results were first announced by the company on October 6, 2014. The results published in The Lancet Oncology describe how vosaroxin plus cytarabine, based on prespecified analyses, is the first regimen to show an overall survival benefit in relapsed/refractory AML, with the benefit observed in patients older than 60 years, a population with limited treatment options. Although no significant difference was observed in the primary endpoint of overall survival (OS) between groups (unstratified analysis, median 7.5 months for vosaroxin and cytarabine [vos/cyt] vs 6.1 months for placebo and cytarabine [pla/cyt], HR=0.87, p=0.061), OS was significantly prolonged in a predefined analysis that stratified by factors used in randomization (stratified log-rank p=0.024). This was supported by a sensitivity analysis of OS censoring for subsequent transplant (median 6.7 months [vos/cyt] vs 5.3 months [pla/cyt], HR=0.81, p=0.024). Prespecified subgroup analyses according to randomization strata demonstrated that OS benefit with vosaroxin was greater in patients age =60 years (7.1 months [vos/cyt] vs 5.0 months [pla/cyt], HR=0.75; p=0.0030). Median OS was not significantly different between treatment arms in patients age <60 years (HR=1.08; p=0.60). The complete remission (CR) rate, the sole secondary efficacy endpoint in the VALOR trial, was significantly greater with vosaroxin (30.1% vs 16.3% with pla/cyt, p<0.0001). Combined complete remission rate was 37.1% and 18.6% for the vos/cyt and pla/cyt treatment arms, respectively (p<0.0001). Prespecified subgroup analyses demonstrated significantly higher response rates for vos/cyt-treated patients across all randomization strata except for those less than 60 years of age, with the most pronounced improvement in patients aged =60 years (CR: 31.9% for vos/cyt vs 13.8% for pla/cyt; p<0.0001). A higher proportion of patients in the vos/cyt arm achieved CR with study drug prior to transplant (48% vos/cyt; 32% pla/cyt). In patients with CR, median leukemia-free survival (LFS) was 11.0 months with vos/cyt vs 8.7 months with pla/cyt (HR=0.89; p=0.63). Event-free survival (EFS) was significantly prolonged in vos/cyt-treated patients (HR=0.67; p<0.0001). Thirty-day and 60-day all-cause mortality was similar in the two treatment arms (30-day: 7.9% vs 6.6%; 60-day: 19.7% vs 19.4% for vos/cyt vs pla/cyt, respectively). Grade 3 and higher adverse events (AEs) were primarily related to myelosuppression, infection, and gastrointestinal events. Serious AEs attributed to study drug were more frequent in the vos/cyt arm, including febrile neutropenia, infections, and gastrointestinal mucosal toxicity. Importantly, there was no increase in the incidence of organ-specific toxicity (cardiac, renal, hepatic, or pulmonary) in the vos/cyt arm compared to the pla/cyt arm.

Sunesis Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Sunesis Pharmaceuticals, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the second quarter, total revenue was $854,000, compared to $1,989,000 for the last year. Loss from operations was $10,623,000, compared to $11,604,000 for the last year. Net loss was $8,949,000 or $0.15 per diluted share, compared to $11,781,000 or $0.20 per diluted share for the last year. For the six months, total revenue was $1,708,000, compared to $3,984,000 for the last year. Loss from operations was $19,392,000, compared to $20,578,000 for the last year. Net loss was $18,077,000 or $0.26 per diluted share, compared to $26,354,000 or $0.45 per diluted share for the last year. Cash used in operations was $19.8 million as compared to $21.6 million for the same period in 2014.

Sunesis Pharmaceuticals, Inc. to Report Q2, 2015 Results on Jul 30, 2015

Sunesis Pharmaceuticals, Inc. announced that they will report Q2, 2015 results on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $1.21 USD +0.15

SNSS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0065 USD 0.00
POZEN Inc $8.85 USD +0.02
View Industry Companies
 

Industry Analysis

SNSS

Industry Average

Valuation SNSS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.4x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.